Barakat Pharmaceutical Group

Barakat Pharmaceutical Group, as the second pharmaceutical holding in the country, with 17 subsidiaries and more than 3600 specialized and committed staff (and creating about 12,000 indirect jobs) and having about 14% of the numerical share of the Iranian pharmaceutical market, has succeeded in Produces and sells 800 product items in 15 different treatment groups.

Barakat Pharmaceutical Group (Public Joint Stock Company) is active in all value chains of the country's pharmaceutical industry, including research and development, production of raw materials, production of final pharmaceutical products, trade and distribution of the final product.

This pharmaceutical group is one of the holdings affiliated to Tadbir Economic Development Group and as one of the largest pharmaceutical knowledge-based holdings in the country in 1389 with a strategic approach to acquire technical knowledge to produce new products and enter emerging therapeutic and pharmaceutical fields in order to realize the vision of Iran 1404 Established. This group was accepted in the list of Tehran Stock Exchange companies in 2016.

In recent years, this group has invested 19,000 billion rials in high-tech fields with the policy of entering new fields of medicine. In this regard, the first and only site for the production of cell therapy products in the region, the first site for the production of injectable anti-cancer drugs in the Mena region, the establishment of the country's first specialized pharmaceutical town equipped with the most advanced drug infrastructure in the world with an area of ​​more than 200 hectares. The production of intermediate drugs and end products in the biological field is part of the success of the Barakat Pharmaceutical Group. Also in the international arena and in line with the macro policies of the group in the field of export, Barakat Pharmaceutical Group in 1399 has exported its products to more than 12 countries around the world. Last year, the registration of more than 40 products in Iraq, Syria and Afghanistan was part of the collection's export achievements.

With the slogan "Health is a blessing", Barakat Pharmaceutical Group always takes steps to provide access to standard medical services and quality pharmaceutical products for all sections of our country, especially the low-income and deprived sections.

The main missions of Barakat Pharmaceutical Group, as the second pharmaceutical holding in the country, in order to realize its vision of becoming a value-creating, innovative and leading economic group in the region, are:

• Development, production and supply of pharmaceutical products
• Investing in new value-added and technological businesses in the field of health with domestic and international participation
• Creating a sustainable competitive advantage in the field of medicine and medical equipment and active presence in regional and international markets
• Research, development and innovation in the field of medicine and medical equipment
• Optimal management of the portfolio of assets and investments

The actions of Barakat Pharmaceutical Group in playing its role in line with social responsibilities in the past year are as follows:

• Helping to reduce the cost of patients in anti-cancer drugs with an annual estimate of 2,000 billion rials
• Providing the bulk of the country's subsidized vaccines required by the Deputy Minister of Health
• Import of emergency and vital medicines such as Angiocatheter and suture
• Import of strategic drugs to meet the needs of special and incurable patients
• Drug distribution in public hospitals despite very heavy arrears
• Obtaining environmental management system certificates in group companies
• Reduction of energy costs by using the new transportation model in subsidiaries
• Holding training courses on energy consumption optimization strategies

Since the arrival of Covid-19 virus and its epidemic in the country, Barakat Pharmaceutical Group has tried to contribute to solving this crisis by using all its scientific, professional, technological and human capacities in order to help the people of our country.

Some of the measures taken by Barakat Pharmaceutical Group in 1399 to fight coronary heart disease are as follows:

• Production of more than 620,000 liters of alcoholic disinfectant solution
• Production of 50 tons of hand sanitizer gel
• Import of more than 20 million types of breathing masks
• Import of 62,000 protective clothing for medical staff
• Import of 200,000 corona detection kits
• Production of 6 items of various corona treatment drugs
• Import of 2 CT scans
• Import of 21 machines for producing various types of respiratory masks
• Import of 193 ventilators
• Distribution of 120 million latex gloves
• Research and development on corona vaccine from various platforms and its production stages

Barakat Pharmaceutical Town

Creating the necessary infrastructure to create fields of scientific and commercial cooperation, production of pharmaceutical and health products and products with the participation of reputable international companies, centralization of pharmaceutical factories in the country with all infrastructures and providing conditions and facilities for developing the activities of knowledge-based companies to support Experts and graduates of the pharmaceutical industry have always been one of the primary goals of Barakat Pharmaceutical Group. In this regard, Barakat Pharmaceutical Industrial Town with an investment of more than 2700 billion Rials and an area of ​​200 hectares 60 km from Tehran in the Kurdish region of Alborz province in 1995 Has started completing and handing over its lands and in 1399 has handed over 172460 square meters of its lands. It is necessary to explain that so far 60% of the lands of Barakat Pharmaceutical Industrial Town have been sold and first level companies in the pharmaceutical industry of the country and the world have invested in this town.

Sobhan Oncology Company

Sobhan Oncology Pharmaceutical Company, as the first manufacturer of anti-cancer drugs in the Middle East and one of the most modern and advanced, started operating in 2002 in the industrial city of Rasht on a land with an area of approximately 25,000 square meters.

This national project has been achieved by using the scientific and technical knowledge of Iranian experts and the latest technologies, as well as full observance of modern world standards, under the supervision of the German company LSMW.

Shafafarmad Industries Group

Shafafarmad Company is one of the knowledge-based companies in the country's pharmaceutical industry that has started operating with the strategic goal of producing antibiotics in the two main branches of macrolides and penicillin. This company is currently one of the most important pillars of 6-APA production in the country. Shafa Pharmed also owns more than half of the market share for the azithromycin raw material.

In recent months, the company has been operating as one of the research centers for vaccine production in the country with the efforts of capable Iranian specialists around the clock and using the equipment and advanced technologies available in the company. Thank God, the results of this research have so far been successful with the successful completion of the animal testing phases and the entry into phase one of the human testing. The human vaccine testing phase is currently underway, and it is hoped that the results of these round-the-clock efforts will be successful and that we will make Islamic Iran proud in the world by producing the Corona vaccine.

Some of the most important subsidiaries in the field of production and supply of final products of Barakat Pharmaceutical Group:

Sobhan Oncology Group

• Has one of the largest and most up-to-date anti-cancer drug production lines in the Middle East
• Manufacturer of 58 anti-cancer drugs under license from the world's most reputable pharmaceutical companies
• The first manufacturer of injectable anti-cancer drugs in Iran
• Mass production and sale of Remediser product (medicine for coronary heart disease) and export of this product to Syria in 1399
• Quick and easy access of patients to safe, effective and desirable anticancer drugs in Iran
• Production of anti-cancer products, production following the transfer of technical knowledge and technology, production under license and contract production of new and up-to-date drugs in Iran
• Development of the country's anti-cancer drug pipeline, through consulting and research cooperation with domestic and foreign scientific research institutes and universities
• Export of oncology drugs to countries in the region

Alborz medicine

• Specialist in the production of cardiovascular drugs in the country
• Having the largest and most equipped production line of injection molding syringes with modern technology in Iran
• Having the highest growth of financial indicators in the last decade in the country's pharmaceutical industry
• The fifth largest pharmaceutical manufacturer in the country and the most profitable company in the pharmaceutical industry in the last three years

Sobhan medicine

• Specializing in the production of psychiatric drugs and the top brand among manufacturing companies in this field in the country
• Gaining the first rank among pharmaceutical industry companies in terms of sales
• Having an accredited laboratory
• Achieving the first rank of operating profit among the distribution companies of the country and the average monthly sales amounting to 4500 billion Rials

Alborz Balk

• Launching the company's production planets last year with the aim of producing the raw materials needed by the country's pharmaceutical industry and creating foreign exchange savings in order to fulfill the slogan of production leap

Iran Daroo Company

• It is one of the oldest and most well-known pharmaceutical companies in Iran, which was established in 1343
• The sales of Iran Daroo in 1399 reached 313.2 billion rials
• Iran Daroo products in several treatment groups, including: cardiovascular, kidney and urinary tract, antihistamines, analgesics, gastrointestinal and anti-nausea, treatment of impotence, local anesthesia, dermal, metabolic and dietary supplement, neurological, Antibiotics and anti-tuberculosis, hypolipidemic, diuretic and antihypertensive, supplements, hand sanitizer and gel
• The amount of Iran Daroo exports in 1399 was over 840 thousand dollars.

Biusans Farmad

• Leading in the production of raw materials, intermediates and biological end products
• Laying ground for Iran to become the main hub of the region in the market of biotechnology products
• Production of Pentavalan vaccine in the subdivision of Barakat Pharmaceutical Group in cooperation with Pasteur Institute of Iran and its replacement with triple vaccines in cooperation with the Ministry of Health and Medical Education in order to fulfill the social responsibilities of the group

Cell-Tech Farmad

• Entering the field of production of cell therapy and gene therapy products with the opening of the first stem cell production plant in the country and the Middle East and obtaining GMP certification from the Food and Drug Administration in 1397
• Leading in the development of advanced medical products and providing it with international standards to industry actors
• Provide advanced therapies for incurable or incurable diseases (including heart failure, leprosy, cerebral palsy, butterfly disease and GVHD)
• Has the most up-to-date and effective method for treating and improving diseases in the Middle East